Intracellular delivery strategies for microRNAs and potential therapies for human cardiovascular diseases

MicroRNAs (miRNAs) effectively regulate gene expression in cultured cells and human disease models, and such regulation can be blocked with antibodies against miRNAs if miRNA-associated adverse effects occur. Promising findings using miRNAs to prevent disease progression in animal studies give hope...

Full description

Saved in:
Bibliographic Details
Published inScience signaling Vol. 3; no. 146; p. pe40
Main Authors Shi, Michael A, Shi, Guo-Ping
Format Journal Article
LanguageEnglish
Published United States 02.11.2010
Subjects
Animals
Cardiovascular Diseases - drug therapy
Drug Delivery Systems
Humans
Mice
MicroRNAs - administration & dosage
MicroRNAs - therapeutic use
Rats
Online AccessGet more information

Cover

More Information
Summary:MicroRNAs (miRNAs) effectively regulate gene expression in cultured cells and human disease models, and such regulation can be blocked with antibodies against miRNAs if miRNA-associated adverse effects occur. Promising findings using miRNAs to prevent disease progression in animal studies give hope to patients with disorders caused by dysregulated gene expression, such as cardiovascular diseases. Inflammatory cell infiltration, endothelial cell dysfunction, and angiogenesis are common pathologies of cardiovascular diseases. Accumulating data suggest that miRNA-mediated inhibition of gene expression can drive these pathologies in cardiac tissue or vasculature. It is often desirable to deliver exogenously prepared miRNAs or antibodies against miRNAs to target genes or miRNAs in specific cell or tissue types. Because naked miRNAs or antibodies against miRNAs are often unstable in the circulation, investigation has focused on their packaging and efficient delivery to diseased organs.
ISSN:1937-9145
DOI:10.1126/scisignal.3146pe40